Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;17(1):81-6.
doi: 10.3747/co.v17i1.473.

Management of hot flashes in women with breast cancer

L Kligman  1 , J Younus
Affiliations

Management of hot flashes in women with breast cancer

L Kligman et al. Curr Oncol. 2010 Feb.

Abstract

Hormone-suppression therapies are used for the treatment of breast cancer in the adjuvant and metastatic settings alike. However, side effects-including hot flashes-are frequently reported by patients as a cause of therapy discontinuation. This paper presents an overview of hormonal therapies and the evidence-based management options for hot flashes, summarized in a treatment algorithm.

Keywords: Breast cancer; aromatase inhibitors; hot flashes; tamoxifen.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Treatment algorithm for hot flashes, based on the experience of the London Regional Cancer Program.
See this image and copyright information in PMC

References

    1. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92:2247–58. - PubMed
    1. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study big 1-98. J Clin Oncol. 2007;25:486–92. - PubMed
    1. Coombes RC, Hall E, Gibson LJ, et al. on behalf of the Inter-group Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–92. - PubMed
    1. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–6. - PubMed
    1. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993;168:772–80. - PubMed

LinkOut - more resources